

# PHILADELPHIA, PA

# \$614,782

Funding for AR Activities  
Fiscal Year 2018



1 local CDC fellow

HIGHLIGHTS

## FUNDING TO STATE HEALTH DEPARTMENTS



\$498,878

### **RAPID DETECTION AND RESPONSE to novel or high-concern drug-resistant germs is critical to contain the spread of these infections.**

With 2017 funding, Philadelphia responded after a frequent intensive care unit (ICU) visitor was hospitalized with active tuberculosis acquired abroad. Philadelphia assessed approximately 400 potentially exposed persons including patients, other visitors, staff, and individuals who stayed at a residential facility that provides housing for out-of-town family members.

### **HAI/AR PREVENTION works best when public health and healthcare facilities partner together to implement targeted, coordinated strategies to stop infections and improve antibiotic use.**

With 2017 funding, Philadelphia increased capacity for prevention by launching a collaborative comprising short- and long-term acute care hospitals and long-term care facilities. This group will enhance coordination, antibiotic use, and timely response to emerging threats.



\$115,904

### **GONORRHEA RAPID DETECTION & RESPONSE works with state and local epidemiology and laboratory partners to test for and quickly respond to resistant gonorrhea to stop its spread in high-risk communities.**

With 2018 funding, Philadelphia participates in a sentinel surveillance project, the STD Surveillance Network, monitoring adherence to national gonorrhea treatment guidelines for patients diagnosed and reported with gonorrhea from all provider settings across the state. To help inform national treatment guidelines for gonorrhea, Philadelphia also participates in the Gonococcal Isolate Surveillance Project (GISP), testing how well antibiotics work on laboratory samples from sentinel STD clinics, which are often the first to detect the threat. Select STD clinics in Philadelphia also collect additional samples, including from women and from extragenital sites, to further enhance surveillance for antibiotic resistant gonorrhea.